Authors: MCLEAN A BROWNE S ZHANG YX SLAUGHTER E HALSTENSON C COUCH R

Citation: A. Mclean et al., BIOAVAILABILITY OF A TWICE-DAILY CONTROLLED-RELEASE CARBAMAZEPINE - INFLUENCE OF FOOD, DOSE EQUIVALENCY, AND DOSE PROPORTIONALITY, Annals of neurology, 44(3), 1998, pp. 224-224

Authors: DIMMITT DC SHAH AK ARUMUGHAM T CRAMER IB HALSTENSON C HORTON M WEIR SJ

Citation: Dc. Dimmitt et al., PHARMACOKINETICS OF ORAL AND INTRAVENOUS DOLASETRON MESYLATE IN PATIENTS WITH RENAL IMPAIRMENT, Journal of clinical pharmacology, 38(9), 1998, pp. 798-806

Authors: KHAN MA HARDEY G STPETER JV PHELEY A HALSTENSON C NICOL S

Citation: Ma. Khan et al., IMPROVEMENT OF CARDIOVASCULAR-DISEASE RISK-FACTORS IN OBESE-DIABETIC AND NONDIABETIC PATIENTS AFTER 12 MONTHS OF PHENTERMINE FENFLURAMINE (PHEN/FEN) THERAPY/, The American journal of clinical nutrition, 66(1), 1997, pp. 111-111

Authors: SHAH J BULLINGHAM R RICE P TSINA I SWAN S HALSTENSON C

Citation: J. Shah et al., PHARMACOKINETICS OF ORAL MYCOPHENOLATE MOFETIL (MMF) AND METABOLITES IN RENALLY IMPAIRED PATIENTS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 149-149

Authors: SWAN SK RADWANSKI E CUTLER D AFFRIME M SCOTT M HALSTENSON C

Citation: Sk. Swan et al., PHARMACOKINETICS OF FLUTAMIDE (F) IN PATIENTS WITH RENAL-INSUFFICIENCY (RI), Clinical pharmacology and therapeutics, 55(2), 1994, pp. 207-207